Extraskeletal myxoid chondrosarcoma (EMC) is an extremely rare soft tissue sarcoma, marked by a translocation involving the NR4A3 gene. EMC is usually indolent and moderately sensitive to anthracycline-based chemotherapy. Recently, we reported on the therapeutic activity of sunitinib in a series of EMC cases, however the molecular target of sunitinib in EMC is unknown. Moreover, there is still the need to identify alternative therapeutic strategies. To better characterize this disease, we performed whole transcriptome sequencing in five EMC cases. Peculiarly, in one sample, an in-frame deletion (c.1735_1737delGAT p.D579del) was identified in exon 11 of KIT. The deletion was somatic and heterozygous and was validated both at DNA and mRNA level. This sample showed a marked high expression of KIT at the mRNA level and a mild phosphorylation of the receptor. Sanger sequencing of KIT in additional 15 Formalin Fixed Paraffin Embedded (FFPE) EMC did not show any other mutated cases. In conclusion, exon 11 KIT mutation was detected only in one out of 20 EMC cases analyzed, indicating that KIT alteration is not a recurrent event in these tumors and cannot explain the EMC sensitivity to sunitinib, although it is an actionable mutation in the individual case in which it has been identified.

Urbini, M., Indio, V., Astolfi, A., Tarantino, G., Renne, S.L., Pilotti, S., et al. (2018). Identification of an actionable mutation of kit in a case of extraskeletal myxoid chondrosarcoma. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 19(7), 1855-1861 [10.3390/ijms19071855].

Identification of an actionable mutation of kit in a case of extraskeletal myxoid chondrosarcoma

Urbini, Milena;Indio, Valentina;Astolfi, Annalisa;Tarantino, Giuseppe;Nannini, Margherita;Saponara, Maristella;MURRONE, LUDOVICA;COLOMBO, CHIARA;Pession, Andrea;Pantaleo, Maria Abbondanza
2018

Abstract

Extraskeletal myxoid chondrosarcoma (EMC) is an extremely rare soft tissue sarcoma, marked by a translocation involving the NR4A3 gene. EMC is usually indolent and moderately sensitive to anthracycline-based chemotherapy. Recently, we reported on the therapeutic activity of sunitinib in a series of EMC cases, however the molecular target of sunitinib in EMC is unknown. Moreover, there is still the need to identify alternative therapeutic strategies. To better characterize this disease, we performed whole transcriptome sequencing in five EMC cases. Peculiarly, in one sample, an in-frame deletion (c.1735_1737delGAT p.D579del) was identified in exon 11 of KIT. The deletion was somatic and heterozygous and was validated both at DNA and mRNA level. This sample showed a marked high expression of KIT at the mRNA level and a mild phosphorylation of the receptor. Sanger sequencing of KIT in additional 15 Formalin Fixed Paraffin Embedded (FFPE) EMC did not show any other mutated cases. In conclusion, exon 11 KIT mutation was detected only in one out of 20 EMC cases analyzed, indicating that KIT alteration is not a recurrent event in these tumors and cannot explain the EMC sensitivity to sunitinib, although it is an actionable mutation in the individual case in which it has been identified.
2018
Urbini, M., Indio, V., Astolfi, A., Tarantino, G., Renne, S.L., Pilotti, S., et al. (2018). Identification of an actionable mutation of kit in a case of extraskeletal myxoid chondrosarcoma. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 19(7), 1855-1861 [10.3390/ijms19071855].
Urbini, Milena*; Indio, Valentina; Astolfi, Annalisa; Tarantino, Giuseppe; Renne, Salvatore Lorenzo; Pilotti, Silvana; Dei Tos, Angelo Paolo; Maestro,...espandi
File in questo prodotto:
File Dimensione Formato  
ijms-19-01855.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 1.35 MB
Formato Adobe PDF
1.35 MB Adobe PDF Visualizza/Apri
ijms-19-01855-s001.pdf

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 132.16 kB
Formato Adobe PDF
132.16 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/663396
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 5
social impact